← Research library

Efficacy of Cytoflavin in patients with multiple sclerosis and fatigue

Comparison in people · 2015

What was studied
62 screened; 53 with fatigue allocated to Cytoflavin (20) or conventional therapy (33)
Main finding
The Cytoflavin group’s MFIS score fell from 45.1±4.5 to 29±4.2 (reported within-group p<0.05). The comparator regimen included pentoxifylline, piracetam, meldonium and B vitamins. The result cannot be attributed to either piracetam or meldonium.

Study data at a glance

Participants or experimental model
62 screened; 53 with fatigue allocated to Cytoflavin (20) or conventional therapy (33)
Reported results
The Cytoflavin group’s MFIS score fell from 45.1±4.5 to 29±4.2 (reported within-group p<0.05). The comparator regimen included pentoxifylline, piracetam, meldonium and B vitamins. The result cannot be attributed to either piracetam or meldonium.
Study limitations and source details

Study limitations

  • Unequal groups; randomization and blinding are not established.
  • 62 is the screened population, not the number allocated to treatment groups.
  • A within-group change is not a demonstrated between-group effect; fatigue improvement is not disease modification.

Source details

Publisher full text

The summary reflects the results reported in the cited source.

Methods and results reviewed

Sources checked

Citation

Human comparative studyFull text available

O. A. Mialovitska. Efficacy of Cytoflavin in patients with multiple sclerosis and fatigue Ukrainian Medical Journal. Published 18 March 2015

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards